Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bifonazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 10/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | PLA2G1B | P04054 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | IDO1 | P14902 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | MAOA | P21397 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bifonazole SCHEMBL1551534 | 1.00 | CYP17A1 (1.00) | CYP17A1MEN1NR1I2USP2ABCB11 | |
| Bifonazole SCHEMBL36803 | 1.00 | CYP17A1 (1.00) | CYP17A1MEN1NR1I2USP2ABCB11 | |
| Bifonazole SCHEMBL1606037 | 1.00 | CYP17A1 (1.00) | CYP17A1MEN1NR1I2USP2ABCB11 | |
| Bifonazole SCHEMBL7598897 | 1.00 | CYP17A1 (1.00) | CYP17A1MEN1NR1I2USP2ABCB11 | |
| SCHEMBL11349905 | 0.98 | CYP17A1 (1.00) | CYP17A1MEN1NR1I2USP2ABCB11 | |
| SCHEMBL25873391 | 0.92 | CYP17A1 (0.85) | CYP17A1MEN1NR1I2USP2ABCB11 | |
| SCHEMBL738495 | 0.91 | CYP19A1 (1.00) | CYP17A1MEN1NR1I2USP2ABCB11 | |
| SCHEMBL24177881 | 0.91 | CYP17A1 (0.82) | CYP17A1MEN1NR1I2USP2ABCB11 | |
| SCHEMBL11362753 | 0.91 | CYP17A1 (0.85) | CYP17A1MEN1NR1I2USP2ABCB11 | |
| SCHEMBL11353276 | 0.91 | CYP19A1 (0.91) | CYP17A1MEN1NR1I2USP2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2433 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3946279-B1 | STRUCTURED ENCAPSULATED SILICON-CONTAINING PARTICLES | SISAF LTD (GB) | 2025-07-23 | — | — | EP | claimed |
| US-12280032-B2 | Methods and compositions for increasing the potency of antifungal agents | PACIFIC NORTHWEST RESEARCH INSTITUTE (US) | 2025-04-22 | — | — | US | claimed |
| WO-2025076059-A1 | ROCAGLATE DERIVATIVES AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2025-04-10 | — | — | WO | claimed |
| US-20250099557-A1 | ANTIBIOTIC PHARMACEUTICAL COMPOSITION CAPABLE OF SUBCUTANEOUS ADMINISTRATION | SHANGHAI BAO PHARMACEUTICALS CO., LTD. (CN) | 2025-03-27 | — | — | US | claimed |
| WO-2024264012-A1 | BIOAVAILABILITY ENHANCING IONIC LIQUID FORMULATIONS INCLUDING ANTHELMINITIC BENZIMIDAZOLE COMPOUNDS AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-12-26 | — | — | WO | claimed |
| WO-2024264013-A1 | BIOAVAILABILITY ENHANCING IONIC LIQUID FORMULATIONS AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-12-26 | — | — | WO | claimed |
| WO-2024233677-A2 | ANTIFUNGAL COMPOUNDS AND USES THEREOF | DUKE UNIVERSITY (US) | 2024-11-14 | — | — | WO | claimed |
| EP-4374848-A1 | ANTIBIOTIC PHARMACEUTICAL COMPOSITION CAPABLE OF SUBCUTANEOUS ADMINISTRATION | Shanghai Bao Pharmaceuticals Co., Ltd. (CN) | 2024-05-29 | — | — | EP | claimed |
| WO-2024095296-A1 | SOLVENT FREE SOLID ORAL COMPOSITION OF BCS CLASS IV DRUGS | REDASANI VIJAYENDRAKUMAR VIRENDRAKUMAR (IN) | 2024-05-10 | — | — | WO | claimed |
| US-11725227-B2 | Devices and methods for examining drug effects on microorganisms | ESSENLIX CORPORATION (US) | 2023-08-15 | — | — | US | claimed |
| WO-2004082655-A1 | MEDICATED SKIN CLEANSING PRODUCTS COMPRISING AN ANTIMYCOTIC AGENT | AGIS INDUSTRIES (1983) LTD. (IL) | 2004-09-30 | — | — | WO | claimed |
| US-20040131628-A1 | Nucleic acids for the treatment of disorders associated with microorganisms | BRATZLER ROBERT L (US) | 2004-07-08 | — | — | US | claimed |
| US-20030198659-A1 | Fibrous pest control | CORNELL RESEARCH FOUNDATION, INC. | 2003-10-23 | — | — | US | claimed |
| WO-2003061554-A2 | COMPOSITION CONTAINING MOUTAN ROOT BARK EXTRACT AS ACTIVE INGREDIENT | MICRO SCIENCE TECH CO., LTD (KR) | 2003-07-31 | — | — | WO | claimed |
| EP-0827553-B1 | COMBINATIONS OF ACTIVE SUBSTANCES | BAYER AG (DE) | 2002-11-27 | — | — | EP | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0827553-A1 | COMBINATIONS OF ACTIVE SUBSTANCES | BAYER AG (DE) | 1998-03-11 | — | — | EP | claimed |
| WO-1996036739-A1 | COMBINATIONS OF ACTIVE SUBSTANCES | BAYER AKTIENGESELLSCHAFT (DE) | 1996-11-21 | — | — | WO | claimed |
| EP-0310122-B1 | ANTIFUNGAL COMPOSITION | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 1991-07-24 | — | — | EP | claimed |